The Blood Sugar–Heart Connection: Why Insulin Resistance Is a Cardiovascular Problem

When most people think about cardiovascular risk, cholesterol and blood pressure usually come to mind first. But long before lipids or pressure numbers rise, something more subtle and pervasive quietly undermines heart health: insulin resistance. 

This metabolic dysfunction,  where cells become less responsive to insulin, disrupts how the body handles glucose and fat, promoting inflammation, endothelial dysfunction, and a host of changes that raise cardiovascular risk. A functional medicine perspective helps us understand not just the “what” of this connection, but the “why” and “how” , giving us tools to prevent and intervene earlier.

What Is Insulin Resistance (IR)?

Insulin resistance occurs when the body’s cells, especially in muscle, liver, and fat tissue fail to respond effectively to insulin, the hormone that ushers glucose into cells for energy. To compensate, the pancreas produces more insulin, leading to hyperinsulinemia, elevated blood insulin levels that can persist for years before blood sugar becomes obviously elevated. Over time, this imbalance fuels metabolic dysfunction and lays the groundwork for type 2 diabetes, obesity, and cardiovascular disease (CVD) (1, 3).

Importantly, insulin resistance often goes undetected using routine measures like fasting glucose or HbA1c, meaning many people may harbor metabolic dysfunction well before it shows up on standard lab panels.

How Insulin Resistance Drives Cardiovascular Risk

The relationship between insulin resistance and cardiovascular disease isn’t just correlated, it’s causal, with multiple overlapping mechanisms.

1. Endothelial Dysfunction and Atherosclerosis

Endothelial cells line the interior of blood vessels and are critical for vascular tone, inflammation control, and anti-coagulant balance. Insulin normally promotes nitric oxide (NO) production in endothelial cells, supporting vasodilation and healthy blood flow. In insulin-resistant states, this signaling pathway becomes impaired, reducing NO and promoting endothelial dysfunction, a key early step in atherosclerosis (1, 3).

Studies show that insulin resistance predicts subclinical vascular abnormalities like prolonged QT interval, arterial stiffness, and markers of inflammation, all linked to heightened cardiovascular risk (2).

2. Inflammation and Metabolic Stress

Insulin resistance is tightly connected to chronic low-grade inflammation, a recognized driver of plaque formation and cardiovascular events. Elevated circulating insulin and glucose levels contribute to increased expression of inflammatory cytokines and oxidative stress, which further impair endothelial function and accelerate atherosclerosis (1, 3).

Research demonstrates that metabolic dysfunction measured by scores like the metabolic score for insulin resistance (METS-IR) correlates with higher blood pressure and greater prevalence of hypertension, a major cardiovascular risk factor (3).

3. Hypertension and Hemodynamic Stress

Insulin resistance contributes to elevated blood pressure through multiple pathways, including increased sympathetic nervous system activity and sodium retention. Large population studies using indices like METS-IR reveal strong associations between metabolic dysfunction and both systolic and diastolic hypertension as key contributors to cardiovascular risk (3).

4. Dyslipidemia and Lipid Abnormalities

Although traditional cholesterol metrics matter, insulin resistance often drives a characteristic dyslipidemia: high triglycerides, low HDL cholesterol, and an abundance of small, dense LDL particles. These lipid changes promote atherosclerotic plaque buildup and are frequently observed even when LDL cholesterol levels are “normal.” This cluster of changes significantly raises cardiovascular risk (1).

Evidence From Recent Research

Recent peer-reviewed studies deepen our understanding of how insulin resistance manifests as cardiovascular risk:

• A large analysis from the U.S. National Health and Nutrition Examination Survey (NHANES) found that greater insulin resistance, measured by validated indices, was associated with a higher 10-year risk of a first hard atherosclerotic cardiovascular event, independent of traditional risk factors like LDL cholesterol (4).
  
• A cross-sectional analysis in people with coronary artery disease found that insulin resistance correlates with coronary inflammation, a hallmark of plaque instability and cardiovascular events (9).
  
• Emerging evidence shows that surrogate measures of insulin resistance that incorporate triglyceride and glucose levels also align strongly with hypertension and cardiovascular risk, underlining the metabolic roots of heart disease (2, 3).
  
• Meta-analyses support the notion that markers of insulin resistance often predict cardiovascular outcomes more robustly than fasting glucose or insulin alone, underscoring their clinical importance (1, 3).

These findings collectively reinforce that insulin resistance is not just a precursor to diabetes, it’s a significant, independent driver of cardiovascular risk.

Why Functional Medicine Matters for Heart Health

A functional medicine approach doesn’t just treat isolated numbers; it examines how systems interact and what drives disease at a deeper level. In the case of insulin resistance and heart risk, this means evaluating metabolic health, inflammation, vascular function, and lifestyle factors together rather than in isolation.

Functional medicine practitioners focus on personalized risk assessment including insulin sensitivity markers and robust metabolic profiling, which often reveals hidden cardiovascular threats before they manifest as overt disease. This allows for earlier and more targeted interventions.

Functional Strategies to Improve Insulin Sensitivity and Cardiovascular Risk

Addressing insulin resistance through a functional lens involves a mix of lifestyle, behavioral, nutritional, and metabolic strategies:

Nutrition That Supports Metabolic Health

Anti-inflammatory, whole-food dietary patterns like Mediterranean, low glycemic index, or balanced macronutrient diets that improve insulin sensitivity and reduce cardiovascular risk markers. Reducing refined carbohydrates and added sugars helps stabilize blood glucose and lower insulin demand.

Movement and Physical Activity

Regular physical activity enhances glucose uptake in muscle cells independently of insulin, improving insulin sensitivity and reducing cardiovascular strain. Both aerobic exercise and strength training are beneficial.

Stress, Sleep, and Recovery

Chronic stress increases cortisol levels and exacerbates insulin resistance. Prioritizing sleep quality and stress mitigation  through mindfulness, breathwork, or behavioral therapies that supports metabolic regulation and heart resilience.

Targeted Functional Testing

Advanced assessments of insulin resistance (e.g., HOMA-IR, TyG index, METS-IR) can uncover early metabolic dysfunction long before diabetes develops, enabling precision interventions tailored to each individual’s physiology.

Next Steps

Insulin resistance isn’t just about future diabetes, it’s a cardiovascular problem now. If you’re ready to go beyond standard risk scores and address the metabolic drivers of heart disease, book a consultation to build a personalized, functional medicine plan that protects your heart at its roots.

References

1. Abdul-Ghani T, Sattar N. Insulin resistance and cardiovascular disease: mechanisms and opportunities. Front Endocrinol (Lausanne). 2025; PMID: 41268094.
   
2. Zeng J, et al. Association between a metabolic score for insulin resistance and hypertension in US adults. Front Endocrinol. 2025.
   
3. He Y, et al. Metabolic score for insulin resistance and incidence of cardiovascular disease: evidence and mechanisms. Front Endocrinol. 2025.
   
4. Pang S, et al. Life’s Essential 8 and insulin resistance in nondiabetic adults. J Am Heart Assoc. 2024; PMID: ___ (JAHA.123.033997).
5. Yang T, Li G, Wang C, et al. Insulin resistance and coronary inflammation in coronary artery disease. Cardiovasc Diabetol. 2024;23:79.